The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | — | $0 |
| Jul 27, 2026 | Venker Eric | President & Immunovant CEO | Sell(S) | 200K | $34.95 | $7.0M |
| Jul 27, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | $3.85 | $770K |
| Jul 17, 2026 | Oren Ilan | Director | Grant(A) | 775 | — | $0 |
| Jul 17, 2026 | Epperly Melissa B, | Director | Grant(A) | 543 | — | $0 |
| Jul 17, 2026 | Momtazee James C | Director | Grant(A) | 405 | — | $0 |
| Jun 30, 2026 | QVT Financial LP | Insider | Sell(S) | 12K | $35.28 | $437K |
| Jun 30, 2026 | Manchester Keith S | Director | Sell(S) | 200K | $35.45 | $7.1M |
| Jun 30, 2026 | Manchester Keith S | Director | Sell(S) | 12K | $35.28 | $437K |
| Jun 30, 2026 | Gold Daniel Allen | Director | Sell(S) | 12K | $35.28 | $437K |
| Jun 30, 2026 | Sukhatme Mayukh | President & CIO, Director | Tax withholding(F) | 47K | $35.39 | $1.7M |
| Jun 30, 2026 | Torti Frank | President and Vant Chair | Tax withholding(F) | 40K | $35.39 | $1.4M |
| Jun 30, 2026 | Fitzgerald Meghan | Director | Option exercise(M) | 10K | — | $0 |
| Jun 30, 2026 | Fitzgerald Meghan | Director | Sell(S) | 10K | $34.90 | $349K |
| Jun 30, 2026 | Fitzgerald Meghan | Director | Option exercise(M) | 10K | $8.80 | $88K |
| Jun 30, 2026 | Gline Matthew | CEO, Director | Tax withholding(F) | 76K | $35.39 | $2.7M |
| Jun 29, 2026 | QVT Financial LP | Insider | Sell(S) | 600K | $34.59 | $20.8M |
| Jun 29, 2026 | QVT Financial LP | Insider | Sell(S) | 200K | $34.44 | $6.9M |
| Jun 29, 2026 | Manchester Keith S | Director | Sell(S) | 600K | $34.59 | $20.8M |
| Jun 29, 2026 | Manchester Keith S | Director | Sell(S) | 200K | $34.44 | $6.9M |
| Jun 29, 2026 | Gold Daniel Allen | Director | Sell(S) | 600K | $34.59 | $20.8M |
| Jun 29, 2026 | Gold Daniel Allen | Director | Sell(S) | 200K | $34.44 | $6.9M |
| Jun 29, 2026 | Epperly Melissa B, | Director | Option exercise(M) | 18K | — | $0 |
| Jun 29, 2026 | Epperly Melissa B, | Director | Sell(S) | 3K | $34.71 | $95K |
| Jun 29, 2026 | Epperly Melissa B, | Director | Sell(S) | 15K | $34.32 | $515K |
| Jun 29, 2026 | Epperly Melissa B, | Director | Option exercise(M) | 18K | $4.46 | $79K |
| Jun 26, 2026 | QVT Financial LP | Insider | Sell(S) | 325K | $34.07 | $11.1M |
| Jun 26, 2026 | QVT Financial LP | Insider | Sell(S) | 301K | $33.92 | $10.2M |
| Jun 26, 2026 | Manchester Keith S | Director | Sell(S) | 325K | $34.07 | $11.1M |
| Jun 26, 2026 | Manchester Keith S | Director | Sell(S) | 301K | $33.92 | $10.2M |
| Jun 26, 2026 | Gold Daniel Allen | Director | Sell(S) | 325K | $34.07 | $11.1M |
| Jun 26, 2026 | Gold Daniel Allen | Director | Sell(S) | 301K | $33.92 | $10.2M |
| Jun 26, 2026 | Sukhatme Mayukh | President & CIO, Director | Option exercise(M) | 500K | — | $0 |
| Jun 26, 2026 | Sukhatme Mayukh | President & CIO, Director | Sell(S) | 500K | $34.08 | $17.0M |
| Jun 26, 2026 | Sukhatme Mayukh | President & CIO, Director | Option exercise(M) | 500K | $3.85 | $1.9M |
| Jun 25, 2026 | Sukhatme Mayukh | President & CIO, Director | Option exercise(M) | 500K | — | $0 |
| Jun 25, 2026 | Sukhatme Mayukh | President & CIO, Director | Sell(S) | 500K | $34.13 | $17.1M |
| Jun 25, 2026 | Sukhatme Mayukh | President & CIO, Director | Option exercise(M) | 500K | $3.85 | $1.9M |
| Jun 24, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | — | $0 |
| Jun 24, 2026 | Venker Eric | President & Immunovant CEO | Sell(S) | 46K | $33.51 | $1.5M |
| Jun 24, 2026 | Venker Eric | President & Immunovant CEO | Sell(S) | 154K | $33.05 | $5.1M |
| Jun 24, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | $3.85 | $770K |
| Jun 20, 2026 | Humes Jennifer | Chief Accounting Officer | Tax withholding(F) | 4K | $31.43 | $113K |
| Jun 20, 2026 | Pulik Richard | CFO | Tax withholding(F) | 2K | $31.43 | $67K |
| May 22, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | — | $0 |
| May 22, 2026 | Venker Eric | President & Immunovant CEO | Sell(S) | 200K | $30.27 | $6.1M |
| May 22, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | $3.85 | $770K |
| May 20, 2026 | Venker Eric | President & Immunovant CEO | Tax withholding(F) | 34K | $32.41 | $1.1M |
| May 20, 2026 | Pulik Richard | CFO | Tax withholding(F) | 19K | $32.41 | $615K |
| Apr 20, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | — | $0 |
| Apr 20, 2026 | Venker Eric | President & Immunovant CEO | Sell(S) | 200K | $29.59 | $5.9M |
| Apr 20, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | $3.85 | $770K |
| Apr 20, 2026 | Humes Jennifer | Chief Accounting Officer | Grant(A) | 27K | — | $0 |
| Apr 20, 2026 | Humes Jennifer | Chief Accounting Officer | Grant(A) | 29K | — | $0 |
| Apr 20, 2026 | Pulik Richard | CFO | Grant(A) | 84K | — | $0 |
| Apr 20, 2026 | Pulik Richard | CFO | Grant(A) | 61K | — | $0 |
| Apr 17, 2026 | Momtazee James C | Director | Tax withholding(F) | 94 | $29.83 | $3K |
| Apr 17, 2026 | Momtazee James C | Director | Grant(A) | 469 | — | $0 |
| Apr 17, 2026 | Oren Ilan | Director | Tax withholding(F) | 95 | $29.83 | $3K |
| Apr 17, 2026 | Oren Ilan | Director | Grant(A) | 896 | — | $0 |
| Apr 17, 2026 | Epperly Melissa B, | Director | Grant(A) | 670 | — | $0 |
| Apr 16, 2026 | Gline Matthew | CEO, Director | Sell(S) | 290K | $29.16 | $8.4M |
| Apr 8, 2026 | Humes Jennifer | Chief Accounting Officer | Sell(S) | 14K | $28.37 | $384K |
| Mar 31, 2026 | Torti Frank | President and Vant Chair | Tax withholding(F) | 160K | $27.70 | $4.4M |
| Mar 31, 2026 | Sukhatme Mayukh | President & CIO, Director | Tax withholding(F) | 188K | $27.70 | $5.2M |
| Mar 31, 2026 | Gline Matthew | CEO, Director | Tax withholding(F) | 305K | $27.70 | $8.4M |
| Mar 30, 2026 | Sukhatme Mayukh | President & CIO, Director | Option exercise(M) | 1.3M | $11.50 | $15.0M |
| Mar 30, 2026 | Sukhatme Mayukh | President & CIO, Director | Tax withholding(F) | 30K | $26.41 | $787K |
| Mar 30, 2026 | Sukhatme Mayukh | President & CIO, Director | Option exercise(M) | 58K | — | — |
| Mar 30, 2026 | Gline Matthew | CEO, Director | Option exercise(M) | 2.2M | $11.50 | $25.0M |
| Mar 30, 2026 | Gline Matthew | CEO, Director | Tax withholding(F) | 54K | $26.41 | $1.4M |
| Mar 30, 2026 | Gline Matthew | CEO, Director | Option exercise(M) | 97K | — | — |
| Mar 26, 2026 | Fitzgerald Meghan | Director | Option exercise(M) | 70K | $8.80 | $616K |
| Mar 26, 2026 | Fitzgerald Meghan | Director | Sell(S) | 70K | $27.45 | $1.9M |
| Mar 26, 2026 | Fitzgerald Meghan | Director | Option exercise(M) | 70K | — | $0 |
| Mar 20, 2026 | Humes Jennifer | Chief Accounting Officer | Tax withholding(F) | 15K | $27.70 | $402K |
| Mar 20, 2026 | Pulik Richard | CFO | Tax withholding(F) | 2K | $27.70 | $43K |
| Mar 17, 2026 | Venker Eric | President & Immunovant CEO | Sell(S) | 200K | $28.24 | $5.6M |
| Mar 17, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | $3.85 | $770K |
| Mar 17, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | — | $0 |
| Mar 16, 2026 | Epperly Melissa B, | Director | Sell(S) | 42K | $28.68 | $1.2M |
| Feb 23, 2026 | Torti Frank | President and Vant Chair | Option exercise(M) | 587K | $3.85 | $2.3M |
| Feb 23, 2026 | Torti Frank | President and Vant Chair | Sell(S) | 587K | $27.51 | $16.2M |
| Feb 23, 2026 | Torti Frank | President and Vant Chair | Option exercise(M) | 587K | — | $0 |
| Feb 20, 2026 | Torti Frank | President and Vant Chair | Option exercise(M) | 1.0M | $3.85 | $3.9M |
| Feb 20, 2026 | Torti Frank | President and Vant Chair | Sell(S) | 1.0M | $27.15 | $27.5M |
| Feb 20, 2026 | Torti Frank | President and Vant Chair | Option exercise(M) | 1.0M | — | $0 |
| Feb 20, 2026 | Venker Eric | President & Immunovant CEO | Tax withholding(F) | 7K | $27.15 | $191K |
| Feb 20, 2026 | Pulik Richard | CFO | Tax withholding(F) | 1K | $27.15 | $27K |
| Feb 19, 2026 | Torti Frank | President and Vant Chair | Option exercise(M) | 1.4M | $3.85 | $5.4M |
| Feb 19, 2026 | Torti Frank | President and Vant Chair | Sell(S) | 1.4M | $27.42 | $38.4M |
| Feb 19, 2026 | Torti Frank | President and Vant Chair | Option exercise(M) | 1.4M | — | $0 |
| Feb 13, 2026 | QVT Financial LP | Insider | Sell(S) | 225K | $26.50 | $6.0M |
| Feb 13, 2026 | QVT Financial LP | Insider | Sell(S) | 151K | $26.49 | $4.0M |
| Feb 13, 2026 | Gold Daniel Allen | Director | Sell(S) | 225K | $26.50 | $6.0M |
| Feb 13, 2026 | Gold Daniel Allen | Director | Sell(S) | 151K | $26.49 | $4.0M |
| Feb 13, 2026 | Manchester Keith S | Director | Sell(S) | 151K | $26.49 | $4.0M |
| Feb 13, 2026 | Manchester Keith S | Director | Sell(S) | 225K | $26.50 | $6.0M |
| Feb 13, 2026 | Venker Eric | President & Immunovant CEO | Sell(S) | 200K | $26.49 | $5.3M |
| Feb 13, 2026 | Venker Eric | President & Immunovant CEO | Option exercise(M) | 200K | $3.85 | $770K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2020-03-30 → 2026-07-30. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).